Research Articles
Research articles concerning NAFLD are extracted from PubMed. For each individual article, related therapeutic strategies, targets, drugs and associated diseases in NAFLDkb are presented with knowledge graphs.
stats1
stats2
stats3
stats4
Search for:
fibrosis10255 records.
| Article ID | PMID | Source | Title | Publish Year | |
|---|---|---|---|---|---|
| A00001 | 35259705 | Diabetes Metab Syndr | Role of diabetologists in the management of nonalcoholic fatty liver disease: Primary prevention and screening/management of fibrosis and cirrhosis. | 2022 | Details |
| A00010 | 35255811 | BMC Gastroenterol | The effect of daily consumption of probiotic yogurt on liver enzymes, steatosis and fibrosis in patients with nonalcoholic fatty liver disease (NAFLD): study protocol for a randomized clinical trial. | 2022 | Details |
| A00016 | 35252828 | JHEP Rep | Macrophage MerTK promotes profibrogenic cross-talk with hepatic stellate cells via soluble mediators. | 2022 | Details |
| A00020 | 35251901 | Australas J Ultrasound Med | Portal Venous Pulsatility Index as a predictor of fibrosis in patients with non-alcoholic fatty liver disease. | 2021 | Details |
| A00031 | 35250588 | Front Pharmacol | Platelets in Non-alcoholic Fatty Liver Disease. | 2022 | Details |
| A00032 | 35250014 | Ultrasound Q | Clinical Feasibility of Shear Wave Dispersion Slope for Noninvasive Diagnosis of Nonalcoholic Steatohepatitis in Patients With Morbid Obesity: Preliminary Results Using US Shear Wave Elastography. | 2022 | Details |
| A00047 | 35244676 | Am J Clin Nutr | Sex-related association of NAFLD and liver fibrosis with body fat distribution in the general US population. | 2022 | Details |
| A00049 | 35243280 | JHEP Rep | Cellular origins of regenerating liver and hepatocellular carcinoma. | 2021 | Details |
| A00056 | 35240344 | Cell Mol Gastroenterol Hepatol | Activation of Liver mTORC1 Protects Against NASH via Dual Regulation of VLDL-TAG Secretion and De Novo Lipogenesis. | 2022 | Details |
| A00058 | 35238782 | Turk J Gastroenterol | Evaluation of Magnetic Resonance Elastography and Transient Elastography for Liver Fibrosis and Steatosis Assessments in the Liver Transplant Setting. | 2022 | Details |
| A00059 | 35238641 | Proc Natl Acad Sci U S A | Disruption of the circadian clock component BMAL1 elicits an endocrine adaption impacting on insulin sensitivity and liver disease. | 2022 | Details |
| A00061 | 35236351 | Lipids Health Dis | Circulating chemerin levels in metabolic-associated fatty liver disease: a systematic review and meta-analysis. | 2022 | Details |
| A00069 | 35232986 | Sci Rep | Liver injury in non-alcoholic fatty liver disease is associated with urea cycle enzyme dysregulation. | 2022 | Details |
| A00081 | 35227956 | Clin Res Hepatol Gastroenterol | Abnormal liver tests and non-alcoholic fatty liver disease predict disease progression and outcome of patients with Covid-19. | 2022 | Details |
| A00083 | 35226932 | Ultraschall Med | Point Shear Wave Elastography by ElastPQ for Fibrosis Screening in Patients with NAFLD: A Prospective, Multicenter Comparison to Vibration-Controlled Elastography. | 2022 | Details |
| A00088 | 35223941 | Front Nutr | Cumulative Betel Quid Chewing and the Risk of Significant Liver Fibrosis in Subjects With and Without Metabolic Syndrome. | 2022 | Details |
| A00089 | 35223701 | Front Pediatr | Association Between Non-invasive Diagnostic Methods of Liver Fibrosis and Type 2 Diabetes in Pediatric Patients With Non-alcoholic Fatty Liver Disease. | 2022 | Details |
| A00091 | 35222903 | Ther Adv Chronic Dis | Nicotinamide supplementation in diabetic nonalcoholic fatty liver disease patients: randomized controlled trial. | 2022 | Details |
| A00097 | 35220673 | Liver Int | Knowledge of liver fibrosis stage among adults with NAFLD/NASH improves adherence to lifestyle changes. | 2022 | Details |
| A00099 | 35220605 | Hepatology | Metabolic subtypes of nonalcoholic fatty liver disease patients exhibit distinctive cardiovascular risk profiles. | 2022 | Details |
| A00100 | 35220131 | Phytomedicine | 2,3,5,4'-tetrahydroxy-stilbene-2-O-β-D-glucoside ameliorates NAFLD via attenuating hepatic steatosis through inhibiting mitochondrial dysfunction dependent on SIRT5. | 2022 | Details |
| A00101 | 35219732 | Eur J Pharmacol | mTOR as an eligible molecular target for possible pharmacological treatment of nonalcoholic steatohepatitis. | 2022 | Details |
| A00103 | 35218234 | Hepatology | Dual roles of B lymphocytes in murine models of diet-induced non-alcoholic fatty liver disease. | 2022 | Details |
| A00105 | 35218194 | J Nutr | Clinical Intervention to Reduce Dietary Sugar does not Impact Liver Fat in Latino Youth, Regardless of PNPLA3 Genotype: A Randomized Controlled Trial. | 2022 | Details |
| A00106 | 35217953 | Environ Sci Pollut Res Int | Environmental exposure to low-dose perfluorohexanesulfonate promotes obesity and non-alcoholic fatty liver disease in mice fed a high-fat diet. | 2022 | Details |
| A00111 | 35216753 | Lancet Digit Health | Development and validation of an ensemble machine learning framework for detection of all-cause advanced hepatic fibrosis: a retrospective cohort study. | 2022 | Details |
| A00113 | 35216439 | Int J Mol Sci | Heat-Inactivated Akkermansia muciniphila Improves Gut Permeability but Does Not Prevent Development of Non-Alcoholic Steatohepatitis in Diet-Induced Obese Ldlr-/-.Leiden Mice. | 2022 | Details |
| A00116 | 35216100 | Int J Mol Sci | Dysregulation of S-adenosylmethionine Metabolism in Nonalcoholic Steatohepatitis Leads to Polyamine Flux and Oxidative Stress. | 2022 | Details |
| A00117 | 35215517 | Nutrients | Potential Roles and Key Mechanisms of Hawthorn Extract against Various Liver Diseases. | 2022 | Details |
| A00119 | 35213373 | J Alzheimers Dis | Non-Alcoholic Fatty Liver Disease, Liver Fibrosis, and Regional Amyloid-β and Tau Pathology in Middle-Aged Adults: The Framingham Study. | 2022 | Details |
| A00122 | 35213001 | Methods Mol Biol | In Vivo Analysis of Necrosis and Ferroptosis in Nonalcoholic Steatohepatitis (NASH). | 2022 | Details |
| A00128 | 35212995 | Methods Mol Biol | Single Cell RNA Sequencing in NASH. | 2022 | Details |
| A00129 | 35212994 | Methods Mol Biol | Analysis of Liver Responses to Non-alcoholic Steatohepatitis by mRNA-Sequencing. | 2022 | Details |
| A00131 | 35212991 | Methods Mol Biol | Culture of Mouse Liver Ductal Organoids. | 2022 | Details |
| A00132 | 35212989 | Methods Mol Biol | Purification and Isolation of Hepatic Stellate Cells. | 2022 | Details |
| A00138 | 35212982 | Methods Mol Biol | Generation of a Diet-Induced Mouse Model of Nonalcoholic Fatty Liver Disease. | 2022 | Details |
| A00139 | 35212981 | Methods Mol Biol | Histopathological Diagnosis of Nonalcoholic Steatohepatitis (NASH). | 2022 | Details |
| A00142 | 35212074 | J Magn Reson Imaging | Water Specific MRI T1 Mapping for Evaluating Liver Inflammation Activity Grades in Rats With Methionine-Choline-Deficient Diet-Induced Nonalcoholic Fatty Liver Disease. | 2022 | Details |
| A00143 | 35211584 | World J Clin Cases | Nonalcoholic fatty liver disease shows significant sex dimorphism. | 2022 | Details |
| A00146 | 35208576 | Medicina (Kaunas) | The Accuracy of Serum Biomarkers in the Diagnosis of Steatosis, Fibrosis, and Inflammation in Patients with Nonalcoholic Fatty Liver Disease in Comparison to a Liver Biopsy. | 2022 | Details |
| A00152 | 35207770 | J Pers Med | Two-Tier Care Pathways for Liver Fibrosis Associated to Non-Alcoholic Fatty Liver Disease in HIV Mono-Infected Patients. | 2022 | Details |
| A00159 | 35204498 | Diagnostics (Basel) | Diagnostic Modalities of Non-Alcoholic Fatty Liver Disease: From Biochemical Biomarkers to Multi-Omics Non-Invasive Approaches. | 2022 | Details |
| A00163 | 35203662 | Biomedicines | The Concept of Indeterminable NASH Inducted by Preoperative Diet and Metabolic Surgery: Analyses of Histopathological and Clinical Features. | 2022 | Details |
| A00166 | 35203502 | Biomedicines | Impact of Maternal Obesity on Liver Disease in the Offspring: A Comprehensive Transcriptomic Analysis and Confirmation of Results in a Murine Model. | 2022 | Details |
| A00168 | 35203457 | Biomedicines | Hypercoagulability in Patients with Non-Alcoholic Fatty Liver Disease (NAFLD): Causes and Consequences. | 2022 | Details |
| A00170 | 35202771 | Diabetes Res Clin Pract | Dapagliflozin for nonalcoholic fatty liver disease: A systematic review and meta-analysis. | 2022 | Details |
| A00172 | 35201574 | Hepatol Int | Gender differences in the association of body composition and biopsy-proved nonalcoholic steatohepatitis. | 2022 | Details |
| A00173 | 35199429 | HIV Med | "Dangerous liaisons: NAFLD and liver fibrosis increase cardiovascular risk in HIV". | 2022 | Details |
| A00176 | 35197660 | Acta Inform Med | Biochemical Parameters as Predictors of Underlying Liver Disease in Patients with Chronic Kidney Disorders. | 2021 | Details |
| A00186 | 35193993 | Gut Liver | Accuracy of Noninvasive Scoring Systems in Assessing Liver Fibrosis in Patients with Nonalcoholic Fatty Liver Disease: A Systematic Review and Meta-Analysis. | 2022 | Details |
| A00188 | 35192934 | Mol Ther | Dysregulated m6A modification promotes lipogenesis and development of non-alcoholic fatty liver disease and hepatocellular carcinoma. | 2022 | Details |
| A00189 | 35192912 | Diabetes Res Clin Pract | Augmented duodenal levels of sodium/glucose co-transporter 1 are associated with higher risk of nonalcoholic fatty liver disease and noninvasive index of liver fibrosis. | 2022 | Details |
| A00190 | 35192675 | PLoS One | Itemization difference of patient-reported outcome in patients with chronic liver disease. | 2022 | Details |
| A00192 | 35191422 | Chin Med J (Engl) | Hepatocyte nuclear factor 4α in the pathogenesis of non-alcoholic fatty liver disease. | 2022 | Details |
| A00195 | 35190696 | Acta Pharmacol Sin | Updates on novel pharmacotherapeutics for the treatment of nonalcoholic steatohepatitis. | 2022 | Details |
| A00198 | 35189786 | Scand J Gastroenterol | Association of serum vitamin C with liver fibrosis in adults with nonalcoholic fatty liver disease. | 2022 | Details |
| A00201 | 35188871 | Epigenetics | Alterations in DNA methylation associate with fatty liver and metabolic abnormalities in a multi-ethnic cohort of pre-teenage children. | 2022 | Details |
| A00202 | 35188038 | Scand J Gastroenterol | Non-alcoholic fatty liver disease and intestinal immune status: a narrative review. | 2022 | Details |
| A00204 | 35187942 | Rev Esp Enferm Dig | Non-invasive liver fibrosis tests in non-alcoholic fatty liver disease. | 2022 | Details |
| A00205 | 35187676 | J Food Biochem | Chitosan oligosaccharide attenuates hepatic steatosis in HepG2 cells via the activation of AMP-activated protein kinase. | 2022 | Details |
| A00206 | 35187020 | Front Nutr | Association of Serum Vitamin C With NAFLD and MAFLD Among Adults in the United States. | 2022 | Details |
| A00212 | 35183303 | Lancet Diabetes Endocrinol | A global view of the interplay between non-alcoholic fatty liver disease and diabetes. | 2022 | Details |
| A00218 | 35180651 | Pathol Res Pract | Stage-dependent expression of fibrogenic markers in alcohol-related liver disease. | 2022 | Details |
| A00226 | 35176096 | PLoS One | Lifestyle changes in patients with non-alcoholic fatty liver disease: A systematic review and meta-analysis. | 2022 | Details |
| A00230 | 35174209 | Front Mol Biosci | ER Disposal Pathways in Chronic Liver Disease: Protective, Pathogenic, and Potential Therapeutic Targets. | 2022 | Details |
| A00235 | 35172845 | Nutr Metab (Lond) | Effects of exercise on high-fat diet-induced non-alcoholic fatty liver disease and lipid metabolism in ApoE knockout mice. | 2022 | Details |
| A00236 | 35172328 | J Clin Endocrinol Metab | Growth hormone and insulin-like growth factor I regulation of nonalcoholic fatty liver disease. | 2022 | Details |
| A00237 | 35171499 | Ther Innov Regul Sci | Attitudes of Chinese Patients with Non-alcoholic Fatty Liver Disease Toward Participation in Clinical Trials from a National Multicenter Survey. | 2022 | Details |
| A00249 | 35166009 | Diabetes Obes Metab | Effects of empagliflozin on markers of liver steatosis and fibrosis and their relationship to cardiorenal outcomes. | 2022 | Details |
| A00250 | 35165568 | Cureus | Efficacy of Lipid Ratios and Platelet Distribution Width for Assessment of Liver Fibrosis in Patients With Non-alcoholic Fatty Liver Disease. | 2022 | Details |
| A00251 | 35164657 | Bioengineered | Liraglutide inhibits receptor for advanced glycation end products (RAGE)/reduced form of nicotinamide-adenine dinucleotide phosphate (NAPDH) signaling to ameliorate non-alcoholic fatty liver disease (NAFLD) in vivo and vitro. | 2022 | Details |
| A00253 | 35164140 | Molecules | A Comparison of the Gene Expression Profiles of Non-Alcoholic Fatty Liver Disease between Animal Models of a High-Fat Diet and Methionine-Choline-Deficient Diet. | 2022 | Details |
| A00254 | 35164079 | Molecules | Genistein-Opportunities Related to an Interesting Molecule of Natural Origin. | 2022 | Details |
| A00255 | 35163991 | Molecules | Sitagliptin Is More Effective Than Gliclazide in Preventing Pro-Fibrotic and Pro-Inflammatory Changes in a Rodent Model of Diet-Induced Non-Alcoholic Fatty Liver Disease. | 2022 | Details |
| A00266 | 35160329 | J Clin Med | Influence of Body Mass Index, Cancer Type and Treatment on Long-Term Metabolic and Liver Outcomes in Childhood Cancer Survivors. | 2022 | Details |
| A00268 | 35160087 | J Clin Med | Crosstalk between Irisin Levels, Liver Fibrogenesis and Liver Damage in Non-Obese, Non-Diabetic Individuals with Non-Alcoholic Fatty Liver Disease. | 2022 | Details |
| A00273 | 35158055 | Clin Gastroenterol Hepatol | Statin Use and Reduced Hepatocellular Carcinoma Risk in Patients With Nonalcoholic Fatty Liver Disease. | 2022 | Details |
| A00274 | 35157960 | J Hepatol | Hepatic lymphatic vascular system in health and disease. | 2022 | Details |
| A00279 | 35154005 | Front Endocrinol (Lausanne) | Novel Subgroups and Chronic Complications of Diabetes in Middle-Aged and Elderly Chinese:A Prospective Cohort Study. | 2022 | Details |
| A00281 | 35153138 | Hepatobiliary Pancreat Dis Int | Prevalence and characteristics of MAFLD in Chinese adults aged 40 years or older: A community-based study. | 2022 | Details |
| A00282 | 35152974 | Adv Clin Chem | Advances in fibrosis biomarkers in nonalcoholic fatty liver disease. | 2021 | Details |
| A00283 | 35152674 | Zhonghua Gan Zang Bing Za Zhi | [Study on the diagnostic value of transient elastography, APRI and FIB-4 for liver fibrosis in children with non-alcoholic fatty liver disease]. | 2022 | Details |
| A00294 | 35148334 | PLoS One | Procollagen C-Proteinase Enhancer-1 (PCPE-1) deficiency in mice reduces liver fibrosis but not NASH progression. | 2022 | Details |
| A00298 | 35146945 | Hepatol Commun | A Genetic and Metabolic Staging System for Predicting the Outcome of Nonalcoholic Fatty Liver Disease. | 2022 | Details |
| A00305 | 35143711 | Clin Transl Sci | Hepatoprotective effects of semaglutide, lanifibranor and dietary intervention in the GAN diet-induced obese and biopsy-confirmed mouse model of NASH. | 2022 | Details |
| A00306 | 35143562 | PLoS One | Rural-Urban differentials in prevalence, spectrum and determinants of Non-alcoholic Fatty Liver Disease in North Indian population. | 2022 | Details |
| A00310 | 35142988 | Curr Gastroenterol Rep | Models to Predict Development or Recurence of Hepatocellular Carcinoma (HCC) in Patients with Advanced Hepatic Fibrosis. | 2022 | Details |
| A00321 | 35137416 | J Cell Physiol | The role of exosomal miRNA in nonalcoholic fatty liver disease. | 2022 | Details |
| A00332 | 35133032 | FASEB J | TCF7L2 transcriptionally regulates Fgf15 to maintain bile acid and lipid homeostasis through gut-liver crosstalk. | 2022 | Details |
| A00337 | 35129841 | Hepatol Res | The potential of soluble CD14 in discriminating nonalcoholic steatohepatitis from nonalcoholic fatty liver disease. | 2022 | Details |
| A00338 | 35129307 | Liver Int | Anti-CD47 antibody treatment attenuates liver inflammation and fibrosis in experimental non-alcoholic steatohepatitis models. | 2022 | Details |
| A00346 | 35126843 | World J Hepatol | Is there a role of lipid-lowering therapies in the management of fatty liver disease? | 2022 | Details |
| A00347 | 35126317 | Front Endocrinol (Lausanne) | Prevalence and Trends in Low Bone Density, Osteopenia and Osteoporosis in U.S. Adults With Non-Alcoholic Fatty Liver Disease, 2005-2014. | 2022 | Details |
| A00354 | 35124268 | Clin Gastroenterol Hepatol | Mendelian Randomization Analysis Reveals No Causal Relationship Between Nonalcoholic Fatty Liver Disease and Severe COVID-19. | 2022 | Details |
| A00355 | 35123096 | Clin Gastroenterol Hepatol | Two-Step Strategy, FIB-4 Followed by Magnetic Resonance Elastography, for Detecting Advanced Fibrosis in NAFLD. | 2022 | Details |
| A00364 | 35118444 | touchREV Endocrinol | Potential Role of Dexamphetamine in the Treatment of Non-alcoholic Fatty Liver Disease: Hopes and Pitfalls. | 2021 | Details |
| A00367 | 35115947 | Front Pharmacol | Gentiana scabra Restrains Hepatic Pro-Inflammatory Macrophages to Ameliorate Non-Alcoholic Fatty Liver Disease. | 2022 | Details |
| A00370 | 35115498 | Cell Death Discov | Bdh1 overexpression ameliorates hepatic injury by activation of Nrf2 in a MAFLD mouse model. | 2022 | Details |
| A00371 | 35114889 | Organogenesis | Therapeutic Potential of HNF4α in End-stage Liver Disease. | 2021 | Details |
| A00375 | 35111794 | Front Nutr | Impact of Sarcopenia on the Severity of the Liver Damage in Patients With Non-alcoholic Fatty Liver Disease. | 2022 | Details |